Key result
Soluble CD40L and oncostatin-M fail to predict 6-month restenosis risk despite ties to vascular markers.
Why the study?
The associations of circulating oncostatin-M and soluble CD40 ligand with fibrinogen, soluble cell adhesion molecules, restenosis, and platelet activation in peripheral arterial occlusive disease were unclear.
Are circulating oncostatin-M and soluble CD40 ligand associated with endothelial activation, platelet activation, and restenosis in patients with peripheral arterial occlusive disease undergoing angioplasty?
Population
71 patients with peripheral arterial occlusive disease undergoing peripheral angioplasty
Comparison
Patients with high versus low soluble CD40L and detectable versus undetectable oncostatin-M
Design
Observational cohort study
Follow-up
6 months
Authors
Loading...
Supports sCD40L as endothelial activation marker in PAOD; leaves open predictive value for post-angioplasty restenosis.
Observational (n=71)
Are circulating oncostatin-M and soluble CD40 ligand associated with endothelial activation, platelet activation, and restenosis in patients with peripheral arterial occlusive disease undergoing angioplasty?
Soluble CD40L is associated with markers of endothelial activation in patients with peripheral arterial disease, though neither CD40L nor OSM predict restenosis after angioplasty.
Tsakiris et al. (2000) conducted an observational in Peripheral arterial occlusive disease (n=71). Soluble CD40 ligand and circulating oncostatin-M vs. Low or undetectable levels was evaluated on Restenosis within 6 months (>50% reduction of lumen). High soluble CD40L was associated with higher soluble VCAM-1 (P<0.01) and thrombomodulin (P<0.01), but neither CD40L nor oncostatin-M levels were associated with 6-month restenosis rates.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: